UBS Group
ELOS

UBS Group’s Syneron Medical Ltd ELOS Stock Holding History

UBS Group’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,250
Closed -$14K – 8356
2017
Q2 		$14K Sell
1,250
-42
-3% -$461 ﹤0.01% 6580
2017
Q1 		$14K Sell
1,292
-887
-41% -$8.58K ﹤0.01% 6431
2016
Q4 		$18K Buy
2,179
+1,929
+772% +$15.1K ﹤0.01% 6604
2016
Q3 		$2K Sell
250
-3,248
-93% -$22.6K ﹤0.01% 7467
2016
Q2 		$27K Buy
+3,498
New +$24.9K ﹤0.01% 6061
2016
Q1 		– Sell
-2,316
Closed -$18K – 8588
2015
Q4 		$18K Buy
2,316
+1,456
+169% +$11.1K ﹤0.01% 6888
2015
Q3 		$6K Sell
860
-2,140
-71% -$20.6K ﹤0.01% 7648
2015
Q2 		$32K Buy
+3,000
New +$35.1K ﹤0.01% 6432
2015
Q1 		– Sell
-586
Closed -$6.49K – 9809
2014
Q4 		$5K Buy
+586
New +$5.65K ﹤0.01% 9041

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

UBS Group's ELOS Position: Q3 2017 in Review

UBS Group sold out of Syneron Medical Ltd (ELOS) in Q3 2017, closing a stake of 1,250 shares — an estimated $14K sold.

UBS Group first reported a position in ELOS in Q4 2014 and held it in 9 quarters. The position peaked at $32K in Q2 2015. 4 funds tracked by Wall St. Rank hold ELOS as of Q3 2017.

  • UBS Group reported no remaining Syneron Medical Ltd position as of Q3 2017 after selling out during the quarter.
  • UBS Group sold 1,250 Syneron Medical Ltd shares in Q3 2017, an estimated $14K.
  • UBS Group first reported a position in Syneron Medical Ltd in Q4 2014 and held it in 9 quarters.
  • UBS Group's Syneron Medical Ltd position peaked at $32K in Q2 2015.
  • 4 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2017.

Based on UBS Group's 13F filing for Q3 2017, filed 14 Nov 2017.